Список литературы

1. FUTURE I/II Study Group, Dillner J., Kjaer S.K., Wheeler C.M. et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: 3493.

2. Eifel P.J., Berek J.S., Markman M.A. Cancer of the cervix, vagina, and vulva. In: De Vita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2011. Pp.: 1311 - 44.

3. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.

4. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989. С. 462.

5. Kurman R., Carcangiu M., Herrington C. WHO Classification of tumours of female reproductive organs. Revised 4^th edn. Lyon: IARC Press, 2014.

6. Коржевская Е.В., Кузнецов В.В., Грицай А.Н. Злокачественные опухоли влагалища. Клиническая онкогинекология: руководство для врачей под ред. В.П. Козаченко. 2-е изд., перераб. и доп. М.: Издательство Бином, 2016. С. 97 - 108.

7. Gallup D.G., Talledo O.E., Shah K.J., Hayes C. Invasive squamous cell carcinoma of the vagina: a 14-year study. Obstet Gynecol 1987; 69(5): 782 - 5.

8. Perez C.A., Gersell D.J., McGuire W.P., Morris M. Vagina. In: Hoskins W.J., Perez C.A., Young R.C., eds. Principles and Practice of Gynecologic Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins, 2000. Pp.: 811 - 40.

9. Frank S.J., Jhingran A., Levenback C. et al. Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 2005; 62 (1): 138 - 47.

10. Stock R.G., Chen A.S., Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 1995; 56 (1): 45 - 52.

11. Perez C.A., Camel H.M., Galakatos A.E. et al. Definitive irradiation in carcinoma of the vagina: long-term evaluation of results. Int J Radiat Oncol Biol Phys 1988; 15 (6): 1283 - 90.

12. Tran P.T., Su Z., Lee P. et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol 2007; 105 (3): 641 - 9.

13. Frank C.A., Korba A., Sharma S. Dosimetricconsiderations in irradiation of carcinoma of the vagina. Int J Radiat Oncol Biol Phys 1977; 62: 138 - 47.

14. Rubin S.C., Young J., Mikuta J.J. Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. Gynecol Oncol 1985; 20 (3): 346 - 53.

15. Raitanen M., Rantanen V., Kulmala J. et al. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro Int J Cancer 2002; 100: 238 - 43.

16. Koh WJ et al. Vulvar Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology./https://www.nccn.org/professionals/physician_gls/pdf/vulvar_blocks.pdf

17. Chung H.C., Ros W., Delord J.P. et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol 2019; 37 (17): 1470 - 8.

18. Chyle V., Zagars G.K., Wheeler J.A. et al. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 1996; 35 (5): 891 - 905.

19. Lian J., Dundas G., Carlone M. et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 2008; 111 (2): 298 - 306.

20. Andersen E.S. Primary carcinoma of the vagina: a study of 29 cases. Gynecol Oncol 1989; 33 (3): 317 - 20.

21. Grigsby P.W. Vaginal cancer. Curr Treat Options Oncol 2002; 3 (2): 125 - 30.

22. Dalrymple J.L., Russell A.H., Lee S.W. et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer 2004; 14 (1): 110 - 7.

23. Samant R., Lau B., Choan E. et al. Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 2007; 69 (3): 746 - 50.

24. Tabata T., Takeshima N., Nishida H. et al. Treatment failure in vaginal cancer. Gynecol Oncol 2002; 84 (2): 309 - 14.

25. Tjalma W.A., Monaghan J.M., de Barros Lopes A. et al. The role of surgery in invasive squamous carcinoma of the vagina. Gynecol Oncol 2001; 81 (3): 360 - 5.

26. Mell L.K., Mundt A.J. Survey of IMRT use in the United States, 2004. Cancer J 2005; 104: 1296 - 303.

27. Benedetti Panici P., Bellati F., Plotti F. et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecol Oncol 2008; 111 (2): 307 - 11.

28. Salani R., Backes F.J., Fung M.F. et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncologists recommendations. Am J Obstet Gynecol 2011; 204 (6): 466 - 78.

29. Mell L.K., Mundt A.J. Survey of IMRT use in the United States, 2004. Cancer J 2005; 104: 1296 - 303.

30. Каприн А.Д., Мардынский Ю.С. Терапевтическая радиология: национальное руководство. М.: ГОЭТАР-Медиа, 2018. 704 с.

31. Труфанов Г.Е., Асатурян М.А., Жаринов Г.М. Лучевая терапия: учебник. Т. 2. М.: ГЭОТАР-Медиа, 2010; 192 с.

32. Thigpen J.T., Blessing J.A., Homesley H.D. et al. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a gynecologic oncology group study. Gynecol Oncol 1986; 23 (1): 101 - 4.

33. Cancer Facts and Figures. ACS 2016.

34. Хохлова С.В., Коломиец Л.А., Кравец О.А. и др. Практические рекомендации по лекарственному лечению рака шейки матки. Злокачественные опухоли: Практические рекомендации. RUSSCO 2018; 8: 178 - 89.

35. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013; 92 (8): 715 - 27.

36. Nilsson H., U., Bock D. et al. Is preoperative physical activity related to post-surgery recovery? BMJ Open 2016; 6 (1): e007997. DOI: 10.1136/bmjopen-2015-007997.

37. Hijazi Y., Gondal U., Aziz O. et al. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017; 39: 156 - 62. DOI: 10.1016/j.ijsu.2017.01.111.

38. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015; 22(13): 4117 - 23. DOI: 10.1245/s10434-015-4550-z.

39. Carter J. Fast-Track Surgery in Gynaecology and Gynaecologic Oncology: A Review of a Rolling Clinical Audit. ISRN Surg 2012; 2012 (368014): 19.

40. Nelson G., Bakkum-Gamez J., Kalogera E. et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations - 2019 update. Int J Gynecol Cancer 2019. DOI: 10.1136/ijgc-2019-000356.

41. De Almeida E.P.M., de Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017; 119 (5): 900 - 7.

42. Wren S.M., Martin M., Yoon J.K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010; 210 (4): 491 - 5.

43. Peedicayil A., Weaver A., Li X., Carey E. et al. Incidence and timing of venous thromboembolism after surgery for gynecological cancer. Gynecol Oncol 2011; 121 (1): 64 - 9.

44. Swarm R., Abernethy A.P., Anghelescu D.L. et al. NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw 2010; 8: 1046 - 86.

45. Ben-Arye E., Samuels N., Lavie O. Integrative medicine for female patients with gynecologic cancer. J Altern Complement Med 2018; 24 (9, 10): 881 - 9.

46. Goerling U., Jaeger C., Walz A. et al. The efficacy of psycho-oncological interventions for women with gynaecological cancer: a randomized study. Oncology 2014; 87: 114 - 24.

47. Smits A., Lopes A., Bekkers R. et al. Body mass index and the quality of life of endometrial cancer survivors - a systematic review and meta-analysis. Gynecol Oncol 2015; 137: 180 - 7. DOI: 10.1016/j.ygyno.2015.01.540.

48. Schmitz K.H., Courneya K.S., Matthews C. et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010; 42 (7): 1409 - 26.

49. Zhou Y., Chlebowski R., La Monte M.J. et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women"s Health Initiative. Gynecol Oncol 2014; 133 (1): 4 - 10.

50. Biglia N., Zanfagnin V., Daniele A. et al. Lower body lymphedema in patients with gynecologic cancer. Anticancer Res 2017; 37 (8): 4005 - 15.

51. Shaitelman S.F., Cromwell K.D., Rasmussen J.C. et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin 2015; 65 (1): 55 - 81. DOI: 10.3322/caac.21253.

52. Borman P. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018; 64 (3): 179 - 97.

53. Zhou M. et al. Tumor regression grading after neoadjuvant chemotherapy predicts long-term outcome of stage IIIC epithelial ovarian cancer./Journal of Clinical Oncology 2018 36: 15_suppl, 5547 - 5547.

54. Kudelka AP, Winn R, Edwards CL, et al.: Activity of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Clin Cancer Res 2 (8): 1285 - 8, 1996.

55. Saito T. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer/Int J Clin Oncol. 2018 Apr; 23 (2): 201 - 234. doi: 10.1007/s10147-017-1193-z. Epub 2017 Nov 20.

56. Shrivastava SB Management of Vaginal Cancer/Rev Recent Clin Trials. 2015; 10 (4): 289 - 97.

57. Schneider S/Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review/Arch Gynecol Obstet. 2019 Nov 25. doi: 10.1007/s00404-019-05321-7.

58. Miralpeix E/Role and impact of multimodal prehabilitation for gynecologic oncology patients in an Enhanced Recovery After Surgery (ERAS) program./Int J Gynecol Cancer. 2019 Oct; 29 (8): 1235 - 1243. doi: 10.1136/ijgc-2019-000597. Epub 2019 Aug 30

59. Kim, Ji-Young et al. "Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival." Obstetrics & gynecology science vol. 56, 6 (2013): 416 - 9. doi: 10.5468/ogs.2013.56.6.416

60. Stock RG, Chen AS, Seski J: A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56 (1): 45 - 52, 1995.

61. Eifel PJ, Klopp AH, Berek JS, et al.: Cancer of the cervix, vagina, and vulva. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, et al., eds.: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, Pa: Wolters Kluwer, 2019, pp 1171 - 1210.

62. Rose PG., et al. "Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study". Journal of Clinical Oncology 17.9 (1999): 2676 - 2680.

63. Santeufemia D.A. Et al. Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases./Eur J Gynaecol Oncol. 2012; 33 (4): 421 - 422

64. Witteveen P.O.et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group)./Ann Oncol. 2009 Sep; 20 (9): 1511 - 6. doi: 10.1093/annonc/mdp043. Epub 2009

65. Oonk. M. H.M. et al. European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer/Int J Gynecol Cancer 2017; 27: 832Y837

66. Garcia A.A. et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study//Gynecologic oncology. - 2007. - T. 104. - N. 3. - С. 572 - 579.

67. Dou, Peng-Hui et al. "Electrical stimulation on adverse events caused by chemotherapy in patients with cervical cancer: A protocol for a systematic review of randomized controlled trial." Medicine vol. 98, 7 (2019): e14609. doi: 10.1097/MD.0000000000014609

68. Lepori S, Fontanella C, Maltese G et al. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. Annals of Oncology, 2017, 28: mdx372.053.

69. Shields LBE, Gordinier ME Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature./Gynecol Obstet Invest. 2019; 84 (1): 94 - 98. doi: 10.1159/000491090. Epub 2018

70. Rose PG et al Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer./N Engl J Med. 1999 Apr 15; 340 (15): 1144 - 53

71. Piller N., Douglass J., Heidenreich B., Moseley A. Placebo controlled trial of mild electrical stimulation. Journal of Lymphoedema. - 2010. - Vol 5, N 1. - P. 15 - 25.

72. Грушина Т.И. Реабилитация в онкологии: физиотерапия. - М.: ГЭОТАР-Медиа, 2006. - 240 с.